Christi Bird, Senior Industry Analyst, Frost & Sullivan, believes the bleakest outlook provided for the life sciences industry is one without a clear light at the end of the tunnel, and successful companies will buckle down to determine long-term strategies for beating the lackluster numbers expected from a sustained austerity policy.
MANAGEMENT INSIGHT – The Secret to Successful Global Expansion is to Bring Your RATs & CATs Together
Derek Hennecke shares his strategy for getting ahead in the global race by following the RAT/CAT virtuous cycle approach to creating and sustaining global advantage developed by Donald Lessard, Rafael Lucea, and Luis Vives in “Building Your Company’s Capabilities Through Global Expansion,” MIT Sloan Management Review.
ADAPTIVE FOCUSED ACOUSTICS – Scalability of AFA in Nanoemulsions: From Microliters to Continuous Flow
Laura E. Forte and Srikanth Kakumanu, PhD, conduct a study demonstrating that Covaris’ AFA can quickly and easily produce nanoemulsions on sample scales varying from 300 microliters to continuous flow.
IDENTITY HUB – Leveraging Identity Hubs to Speed the Drug Development & Delivery Process & Maximize Revenue Opportunities
Vijay Takanti, MS, MBA, believes the Exostar Life Sciences Identity Hub is a proven implementation of the identity hub concept that provides the trust necessary for enterprises and individuals to collaborate with confidence.
Drug Development Executive: Carol Collins, Corporate Vice President, Strategic Partnerships, PAREXEL, clarifies how Strategic Partnerships differ from other outsourcing approaches – and what makes them more effective.
Derek Hennecke reviews the latest book by Black Swan author Nassim Taleb, indicating it is a thoroughly maddening book. And whether or not you enjoy this type of mental gymnastics, and if it gains anything like the notoriety of his previous books, you’re going to hear about it.
Drug Development Executive: Rod Ray, former Bend Research CEO and now a member of Capsugel’s Scientific and Business Advisory Board, talks about the enhanced capabilities of Capsugel DFS and the advantages offered to companies developing new and/or enhanced medicines.
Roundtable Discussion: Contributor Cindy H. Dubin gathered leading CROs together to discuss the benefits of outsourcing early-stage clinical trials, how to mitigate the risks, and lower costs in the process.
SPECIAL FEATURE – Prefilled Syringes & Parenteral Contract Manufacturing – Product Differentiation Is Critical
Contributor Cindy H. Dubin speaks with several of these suppliers and manufacturers about the importance of customization and differentiation as the key to pharma companies staying competitive in the prefilled syringe space.
CLINICAL DEVELOPMENT STRATEGIES – Optimizing a Full-Package Strategic Alliance for Clinical Development Services
INTRODUCTION Pharmaceutical and biopharmaceutical companies are confronting a fundamental productivity challenge. In the past two decades, R&D cost has increased significantly, yet the rate of…
EXCLUSIVE ONLINE CONTENT
Appili Therapeutics Inc. recently announced it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC on ATI-1501, Appili’s liquid suspension reformulation of the…..
PPD, Inc. has expanded its early development research services by adding significant neuroscience and ethno-bridging expertise, broadening its capabilities to provide increased access to…..
Recipharm, the contract development and manufacturing organisation (CDMO), recently announced ongoing large-scale commercial manufacturing of RedHill Biopharma’s drug, Talicia (omeprazole magnesium,…..
Catalent recently announced it had entered into a long-term commercial supply agreement with BeiGene, Ltd., a biopharmaceutical company focused on developing….
Cytel Inc. recently announced that it has acquired MTEK Sciences to further expand its advanced real-world analytics (RWA) capabilities….